I could be wrong, but just looking across the GBM landscape, I think former adversaries, with few exceptions, are coming round to setting the correct stage for DCVax’s introduction as a viable immunotherapy (perhaps future SOC) for GBM as it is now genetically defined. From Switzerland to UCSF, I think Dr.Liau et al have gradually won over former critics. I think the common purpose finally outweighed the commercial and institutional competiveness, and now the stage is set for DCVax therapy to be embraced globally for GBM as it is now defined.
Market Data 
Markets 
AI
